Literature DB >> 23359271

T-cell immunoglobulin- and mucin-domain-containing molecule 3 gene polymorphisms and prognosis of non-small-cell lung cancer.

Jianwen Bai1, Xiaoyan Li, Danian Tong, Weiwei Shi, Haihan Song, Qinchuan Li.   

Abstract

Lung cancer is the leading cause of death worldwide. Non-small-cell lung cancer (NSCLC) accounts for most of these cases. T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) has been established as a negative regulatory molecule and plays a critical role in immune tolerance. Studies have shown that polymorphisms in TIM-3 gene can be associated with various diseases. The aim of this study was to investigate whether polymorphisms in the TIM-3 gene were associated with susceptibility to NSCLC. Three polymorphisms in TIM-3 gene (-1516G/T, -574G/T, and +4259T/G) were identified by polymerase chain reaction-restriction fragment length polymorphism in 432 NSCLC patients and 466 healthy controls. Results showed that frequencies of TIM-3 +4259TG genotype for cases and controls were 10.9 and 4.1 %, respectively; subjects carrying the +4259TG genotype had a 2.81-fold increased risk of NSCLC compared to the wild-type genotype (P < 0.0001). The TIM-3 -1516G/T and -574G/T polymorphisms did not show any correlation with NSCLC. In addition, when analyzing the survival time of NSCLC patients with TIM-3 +4259T/G polymorphism, cases with +4259TG genotype had significantly shorter survival time compared to the wild-type patients (15.2 months vs. 26.7 months, P = 0.007). These results suggested polymorphism in TIM-3 gene is associated with increased susceptibility to NSCLC and could be used as prognostic factor for this malignancy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23359271     DOI: 10.1007/s13277-012-0610-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  22 in total

1.  Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance.

Authors:  Catherine A Sabatos; Sumone Chakravarti; Eugene Cha; Anna Schubart; Alberto Sánchez-Fueyo; Xin Xiao Zheng; Anthony J Coyle; Terry B Strom; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2003-10-12       Impact factor: 25.606

2.  Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells.

Authors:  Li Wang; Karina Pino-Lagos; Victor C de Vries; Indira Guleria; Mohamed H Sayegh; Randolph J Noelle
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-02       Impact factor: 11.205

3.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

4.  Genetic variations and haplotypes in TIM-3 gene and the risk of gastric cancer.

Authors:  Bangwei Cao; Linzhong Zhu; Shengtao Zhu; Danping Li; Chuanzhen Zhang; Changqing Xu; Shutian Zhang
Journal:  Cancer Immunol Immunother       Date:  2010-09-02       Impact factor: 6.968

5.  The association of TIM-3 gene polymorphism with atopic disease in Korean population.

Authors:  Soo-Cheon Chae; Young-Ran Park; Yong-Chul Lee; Jae-Hoon Lee; Hun-Taeg Chung
Journal:  Hum Immunol       Date:  2004-12       Impact factor: 2.850

6.  TIM-3: a novel regulatory molecule of alloimmune activation.

Authors:  Olaf Boenisch; Francesca D'Addio; Toshihiko Watanabe; Wassim Elyaman; Ciara N Magee; Melissa Y Yeung; Robert F Padera; Scott J Rodig; Takaya Murayama; Katsunori Tanaka; Xueli Yuan; Takuya Ueno; Anke Jurisch; Bechara Mfarrej; Hisaya Akiba; Hideo Yagita; Nader Najafian
Journal:  J Immunol       Date:  2010-10-18       Impact factor: 5.422

7.  The polymorphisms of Th1 cell surface gene Tim-3 are associated in a Korean population with rheumatoid arthritis.

Authors:  Soo-Cheon Chae; Young-Ran Park; Seung-Cheol Shim; Kyung-Sik Yoon; Hun-Taeg Chung
Journal:  Immunol Lett       Date:  2004-08-15       Impact factor: 3.685

8.  Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Authors:  Kaori Sakuishi; Lionel Apetoh; Jenna M Sullivan; Bruce R Blazar; Vijay K Kuchroo; Ana C Anderson
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

9.  Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC.

Authors:  Xuewei Zhuang; Xiaoning Zhang; Xiyan Xia; Cuijuan Zhang; Xiaohong Liang; Lifen Gao; Xin Zhang; Chunhong Ma
Journal:  Am J Clin Pathol       Date:  2012-06       Impact factor: 2.493

10.  TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Authors:  Xin Gao; Yibei Zhu; Gang Li; Haitao Huang; Guangbo Zhang; Fengming Wang; Jing Sun; Qianting Yang; Xueguang Zhang; Binfeng Lu
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  15 in total

1.  TIM-3 Genetic Variations Affect Susceptibility to Osteoarthritis by Interfering with Interferon Gamma in CD4+ T Cells.

Authors:  Shufeng Li; Yanjun Ren; Dayong Peng; Zhen Yuan; Shiying Shan; Huaqiang Sun; Xinfeng Yan; Hong Xiao; Guang Li; Haihan Song
Journal:  Inflammation       Date:  2015-10       Impact factor: 4.092

Review 2.  Targeting novel inhibitory receptors in cancer immunotherapy.

Authors:  Quan-Quan Ding; Joe-Marc Chauvin; Hassane M Zarour
Journal:  Semin Immunol       Date:  2020-12-04       Impact factor: 11.130

3.  Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer.

Authors:  Li Li; Jinshan Zhang; Xin Weng; Ge Wen
Journal:  Tumour Biol       Date:  2014-09-19

4.  Regulatory T cells contribute to the recovery of acute lung injury by upregulating Tim-3.

Authors:  Haihan Song; Yujia Zhou; Guanggang Li; Jianwen Bai
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

Review 5.  Tim-3 and its role in regulating anti-tumor immunity.

Authors:  Madhumita Das; Chen Zhu; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

Review 6.  Tim-3 and Tim-4 as the potential targets for antitumor therapy.

Authors:  Lin Cheng; Zhihua Ruan
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Galectin-9 increases Tim-3+ dendritic cells and CD8+ T cells and enhances antitumor immunity via galectin-9-Tim-3 interactions.

Authors:  Keiko Nagahara; Tomohiro Arikawa; Souichi Oomizu; Keiichi Kontani; Atsuya Nobumoto; Hiroaki Tateno; Kota Watanabe; Toshiro Niki; Shigeki Katoh; Minoru Miyake; Syun-Ichiro Nagahata; Jun Hirabayashi; Vijay K Kuchroo; Akira Yamauchi; Mitsuomi Hirashima
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

8.  Tim-3 expression is increased on peripheral T cells from diffuse large B cell lymphoma.

Authors:  Taiwu Xiao; Li Zhang; Lei Chen; Guozhen Liu; Zhenjun Feng; Lei Gao
Journal:  Tumour Biol       Date:  2014-05-16

9.  Advantages of Molecular Weight Identification during Native MS Screening.

Authors:  Ahad Khan; Anne Bresnick; Sean Cahill; Mark Girvin; Steve Almo; Ronald Quinn
Journal:  Planta Med       Date:  2018-05-09       Impact factor: 3.352

10.  Association between TIM-3 polymorphisms and cancer risk: a meta-analysis.

Authors:  Hongyan Fang; Cheng Yuan; Xinsheng Gu; Qiuju Chen; Dong Huang; Heng Li; Min Sun
Journal:  Ann Transl Med       Date:  2019-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.